Identifying metabolic dependencies in pancreatic cancer
Pancreatic cancers are highly resistant to currently available therapeutics which results in a 5-year survival rate of approximately 6%. We believe that this resistance points toward altered cell metabolic pathways. In this regard we have previously shown that that oncogenic Kras promotes a rewiring of pancreatic cancer metabolism allowing carbon sources to be utilized in a variety of biosynthetic pathways. Importantly, several of these metabolic pathways are critical for tumor growth and therefore represent potential therapeutic targets. Ongoing studies from our group are exploring targeting various aspects of metabolism as therapeutic approaches. Additional studies from our group have demonstrated pancreatic cancers have elevated basal autophagy which is required for their continued growth. Importantly, inhibition of autophagy pharmacologically or genetically leads to decreased oxidative phosphorylation, a drop in ATP production, and ultimately growth inhibition. These findings have implicated autophagy as a key component of pancreatic cancer metabolism and have motivated the opening of multiple clinical trials assessing the efficacy of hydroxychloroquine as an autophagy inhibitor in pancreatic cancer. Recently, we have identified an autophagy-dependent metabolic cross-talk that exists between pancreatic tumor cells and the surrounding stroma. Ongoing work from our group seeks to understand the metabolic contributions that autophagy makes in pancreatic tumors. These and other aspects of pancreatic cancer metabolism will be discussed.
Date: 4 May 2017, 11:00 (Thursday, 2nd week, Trinity 2017)
Venue: NDM Building, Headington OX3 7FZ
Venue Details: TDI, Basement meeting room, NDM Research Building
Speaker: Prof Alec Kimmelman (NYU Langone Medical Center)
Organising department: Ludwig Institute for Cancer Research, Oxford Branch
Organiser: Mary Muers (Oxford Ludwig Institute, NDM Experimental Medicine)
Organiser contact email address:
Host: Dr Sebastian Nijman (Ludwig Cancer Research, Oxford)
Part of: Ludwig Institute Seminar Series
Booking required?: Not required
Audience: Members of the University only
Editor: Mary Muers